Clinical trials advance treatments and care so people with type 1 diabetes (T1D) can live fuller, healthier lives.
Below are a few trials that are ongoing in the Southern California region. If you meet the given eligibility criteria, we encourage you to follow the links provided for additional information about how to apply for the trial.
A Study of GNTI-122 in Adults Recently Diagnosed With T1D (POLARIS)
This study is evaluating the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a participant’s own blood cells in adult participants with recently diagnosed T1D. GNTI-122 is designed to help stop your body from attacking and destroying your beta cells.
Eligibility: Age 18-55 within 180 days of diagnosis
Locations: City of Hope in Duarte, CA AND University of California San Diego
More Info: https://www.polarisstudy.com/
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes (βETA PRESERVE)
The purpose of this study is to measure change in glycemic control and prandial insulin independency over 52 weeks with teplizumab compared with placebo, both administered by intravenous (IV) infusion.
Eligibility: Age 1-25 within 8 weeks of diagnosis
Locations: Radys Children’s Hospital in San Diego (pediatrics patients only); City of Hope in Duarte, CA will soon activate for adults Age 18-25
More info: https://clinicaltrials.gov/study/NCT07088068
Denosumab for Type 1 Diabetes
This is a local Breakthrough T1D funded trial!
This study is evaluating whether denosumab, a drug used to treat bone thinning, is safe and effective treatment to help people with type 1 diabetes make insulin and improve blood sugar control.
Eligibility: Age 18-50 (females); Age 21-50 (males) and within 1 to 5 years of diagnosis
Location: City of Hope in Duarte, CA
More info: https://clinicaltrials.gov/study/NCT06524960
More info: https://clinicaltrials.gov/study/NCT03746769
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
This study will assess the safety, tolerability, pharmacodynamics, and efficacy of multiple ascending doses of CNP-103, an investigational disease-modifying nanoparticle therapy.
Eligibility: Age 12-35 within 6 months of diagnosis
Locations: Rady Children’s Hospital San Diego AND Hoag Memorial Hospital, Newport Beach
More info: https://t1d103clinicalstudy.com/about-study
There are other ongoing Cell Therapy Clinical Trials happening throughout the United States.
Some trials may support travel costs, so we encourage you to explore other trials for which you, or someone you know, may be eligible.
Our local Clinical Trial Education Volunteers are also here to help you with any questions you may have. Feel free to reach out to these dedicated volunteers for additional information and support: